An overview in the treatment of advanced ovarian cancer. MRC Gynaecological Cancer Working Party.
出版信息
Br J Cancer. 1990 Apr;61(4):495-6. doi: 10.1038/bjc.1990.111.
Abstract
摘要
相似文献
1
An overview in the treatment of advanced ovarian cancer. MRC Gynaecological Cancer Working Party.晚期卵巢癌治疗概述。医学研究委员会妇科癌症工作组。
Br J Cancer. 1990 Apr;61(4):495-6. doi: 10.1038/bjc.1990.111.
2
Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?晚期卵巢癌的新辅助化疗：需要何种证据才能说服美国妇科肿瘤学家？
Gynecol Oncol. 2010 Oct;119(1):1-2. doi: 10.1016/j.ygyno.2010.08.011.
3
Gynaecological cancer: ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer.妇科癌症：ADAMTS 突变可预测卵巢癌对化疗的敏感性。
Nat Rev Clin Oncol. 2015 Sep;12(9):504. doi: 10.1038/nrclinonc.2015.122. Epub 2015 Jun 30.
4
Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): a questionnaire survey.英国妇科肿瘤学家治疗原发性晚期上皮性卵巢癌（PAEOC）的手术实践：问卷调查。
Gynecol Oncol. 2013 Nov;131(2):347-51. doi: 10.1016/j.ygyno.2013.08.007. Epub 2013 Aug 13.
5
Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.晚期卵巢癌的化疗。晚期卵巢癌试验组。
Cochrane Database Syst Rev. 2000(2):CD001418. doi: 10.1002/14651858.CD001418.
6
Pharmacoeconomic considerations in treating ovarian cancer.治疗卵巢癌的药物经济学考量
Pharmacoeconomics. 2000 Feb;17(2):133-50. doi: 10.2165/00019053-200017020-00003.
7
8
The results of a quantitative overview of chemotherapy in advanced ovarian cancer: what can we learn?
Bull Cancer. 1993 Feb;80(2):146-51.
9
Medical therapy of advanced malignant epithelial tumours of the ovary.晚期卵巢恶性上皮性肿瘤的医学治疗
Forum (Genova). 2000 Oct-Dec;10(4):323-32.
10
Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.晚期卵巢癌的化疗：随机临床试验综述。晚期卵巢癌试验协作组
BMJ. 1991 Oct 12;303(6807):884-93. doi: 10.1136/bmj.303.6807.884.
本文引用的文献
1
Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer.美法仑与环磷酰胺、甲氨蝶呤和5-氟尿嘧啶在卵巢癌患者中的比较。
Cancer. 1984 Feb 15;53(4):844-52. doi: 10.1002/1097-0142(19840215)53:4<844::aid-cncr2820530405>3.0.co;2-n.
2
Publication bias: the case for an international registry of clinical trials.发表偏倚：建立国际临床试验注册机构的理由。
J Clin Oncol. 1986 Oct;4(10):1529-41. doi: 10.1200/JCO.1986.4.10.1529.
3
Treatment decisions in advanced ovarian cancer.晚期卵巢癌的治疗决策
Br J Cancer. 1989 Aug;60(2):155-6. doi: 10.1038/bjc.1989.241.
4
Publication bias and dissemination of clinical research.发表偏倚与临床研究的传播
J Natl Cancer Inst. 1989 Jan 18;81(2):107-15. doi: 10.1093/jnci/81.2.107.
5
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.卵巢癌初始治疗中肿瘤主体的手术切除。
Natl Cancer Inst Monogr. 1975 Oct;42:101-4.
6
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
N Engl J Med. 1978 Dec 7;299(23):1261-6. doi: 10.1056/NEJM197812072992301.
Zotero 插件